Basilea Stock Takes a Hit on FDA Guidelines for Antibiotic Trials
By Catherine Shaffer
Friday, August 23, 2013
The FDA has maintained a firm stance on clinical trial requirements for Basilea Pharmaceutica Ltd.'s broad-spectrum antibiotic ceftobiprole for skin infections. In its half-year financial update, Basilea indicated that the agency would require two pivotal trials per indication. Basilea's stock (SW:BSLN) closed Thursday at CHF70.75 (US$76.67), down CHF2.45.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.